MAUNA KEA TECHNOLOGIES (EPA:MKEA) MAUNA KEA TECHNOLOGIES APPOINTS AGNÈS ROUFFIAC AS HUMAN RESOURCES DIRECTOR

Transparency directive : regulatory news

13/09/2011 17:45

Press Release

MAUNA KEA TECHNOLOGIES APPOINTS AGNÈS ROUFFIAC AS HUMAN RESOURCES DIRECTOR

PARIS - September 13 2011 - Mauna Kea Technologies (NYSE Euronext: MKEA), leader
in the endomicroscopy market, today announced the appointment of Agnès Rouffiac
as Director, Human Resources.

With her 20 years of experience in sales, marketing and human resource (HR)
management, Ms. Rouffiac will strengthen Mauna Kea Technologies' international
HR strategy.

"We are delighted to welcome Agnès to Mauna Kea Technologies," said Sacha
Loiseau, Mauna Kea Technologies' CEO and founder. "Her expertise in recruiting
top talent to help companies strate gically grow and sustain successful
businesses will be vital as we work to introduce Cellvizio to new markets and
deepen our footprint in healthcare markets where endomicrosopy is currently
utilized."

"I am delighted to be joining Mauna Kea Technologies. Following the recent
successful IPO, the company is entering an incredibly exciting phase. I believe
my expertise in recruitment, business growth and organizational planning will
help support the company's business strategy to increase utilization of
endomicroscopy in Europe and the rest of the world to ultimately benefit
patients and the company's shareholders," Ms. Rouffiac said.

Ms. Rouffiac comes to Mauna Kea from Reckitt Benckiser, the world leader in
cleaning and hygiene products, where she worked in roles of increasing
responsibility for the last two decades. Most recently, she led HR for Reckitt
Beckinser's only industrial facility in France, which employs an estimated 400
people. For the first decade of her career at Reckitt Benckiser, she held key
roles in marketing, as a product manager and category leader. In 2002, she was
promoted to Trade Marketing Director. Two years later, she began her career as
an HR Manager within the same group. Agnès is a graduate of HEC Paris business
school and also obtained a Master's in Economics in Brazil (Pontifícia
Universidade Católica). She is fluent in French, English and Portuguese.

About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company and leader in the
endomicroscopy market. The company researches, develops and markets innovative
tools to visualize and detect abnormalities in the gastro-intestinal and
pulmonary tracts. Its flagship product, Cellvizio(r), a probe-based Confocal
Laser Endomicroscopy (pCLE) system, provides physicians and researchers high
resolution cellular views of tissue inside the body. Large, international,
multi-center clinical trials have demonstrated Cellvizio's ability to help
physicians more accurately detect early forms of disease and make treatment
decisions immediately. Designed to improve patient outcomes and reduce costs
within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio
has 510(k) clearance from the U.S. Food and Drug Administration and the European
CE-Mark for use in the GI and pulmonary tracts.

For more information about Mauna Kea Technologies visit www.maunakeatech.com

Disclaimer
This press release and the information contained herein do not constitute an
offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe
to, shares in Mauna Kea Technologies ("the Company") in any country. This press
release contains forward-looking statements that relate to the Company's
objectives. Such forward-looking statements are based solely on the current
expectations and assumptions of the Company's management and involve risk and
uncertainties. Potential risks and uncertainties include, without limitation,
whether the Company will be successful in implementing its strategies, whether
there will be continued growth in the relevant market and demand for the
Company's products, new products or technological developments introduced by
competitors, and risks associated with managing growth. Unfavorable developments
in connection with these and other risks and uncertainties described, in
particular, in the Company's prospectus prepared in connection with its IPO and
on which the French Autorité des marches financiers ("AMF") granted its visa
number 11-236 on June 230, 2011, could cause the Company to fail to achieve the
objectives expressed by the forward-looking statements above.

Media Contacts:

U.S. media
Lazar Partners Ltd.
Erich Sandoval
Tel.: +1 917 497 2867
E-mail: esandoval@lazarpartners.com

Mauna Kea Technologies
Alexander Bryson
Marketing Communications and Brand Manager
Tel: +33 1 70 08 09 92
E-mail: alexander@maunakeatech.com

French/European media
ALIZE RP
Caroline Carmagnol
Tel.: +33 1 42 68 86 43 // +33 6 64 18 99 59
caroline@alizerp.com
Anne -Sophie Cosquéric
Tel.: +33 1 42 68 86 41
anne-sophie@alizerp.com

MAUNA KEA TECHNOLOGIES's latest news

25/04/2024 20:50

MAUNA KEA TECHNOLOGIES (EPA:MKEA) MAUNA KEA TECHNOLOGIES APPOINTS AGNÈS ROUFFIAC AS HUMAN RESOURCES DIRECTOR

Transparency directive : regulatory news

MAUNA KEA TECHNOLOGIES's latest news

Other stories